We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

69 hedge funds and large institutions have $94.1M invested in Aevi Genomic Medicine Inc in 2016 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 15 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

650% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 2

73% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 15

59% more capital invested

Capital invested by funds: $59.4M → $94.1M (+$34.8M)

23% more funds holding

Funds holding: 56 → 69 (+13)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
69
Holders Change
+13
Holders Change %
+23.21%
% of All Funds
1.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
26
Reduced
15
Closed
2
Calls
$99K
Puts
–
Net Calls
+$99K
Net Calls Change
+$99K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.46M
2
SFM
Sphera Funds Management
Israel
+$2.36M
3
OM
Opaleye Management
Massachusetts
+$2.06M
4
BC
Broadfin Capital
New York
+$1.71M
5
PA
Perceptive Advisors
New York
+$1.58M

Top Sellers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
-$239K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$193K
3
AA
ALPS Advisors
Colorado
-$163K
4
QF
QVT Financial
New York
-$98.8K
5
Citigroup
Citigroup
New York
-$96.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
UOC
26
UBS O'Connor
Illinois
$278K +$263K +50,000 New
TC
27
TFS Capital
Pennsylvania
$265K +$169K +32,139 +205%
LPL Financial
28
LPL Financial
California
$247K -$239K -45,458 -51%
Charles Schwab
29
Charles Schwab
California
$245K +$107K +20,300 +86%
SS
30
Sunbelt Securities
Texas
$222K +$210K +40,000 New
TD Asset Management
31
TD Asset Management
Ontario, Canada
$203K – – –
TA
32
Teachers Advisors
New York
$190K +$19.8K +3,774 +12%
RhumbLine Advisers
33
RhumbLine Advisers
Massachusetts
$187K +$80.5K +15,333 +83%
CD
34
Carl Domino
Florida
$185K -$4.52K -861 -3%
OAM
35
Oxford Asset Management
United Kingdom
$128K +$121K +23,059 New
WPC
36
White Pine Capital
Minnesota
$111K – – –
BGA
37
Belmont Global Advisors
Texas
$111K +$105K +20,000 New
Goldman Sachs
38
Goldman Sachs
New York
$93K +$8.79K +1,674 +11%
Jacobs Levy Equity Management
39
Jacobs Levy Equity Management
New Jersey
$88K -$193K -36,700 -70%
VanEck Associates
40
VanEck Associates
New York
$87K -$22.6K -4,295 -21%
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$86K – – –
CDH
42
Charles D. Hyman
$84K – – –
Wells Fargo
43
Wells Fargo
California
$78K -$2.15K -409 -3%
AIG
44
American International Group
New York
$77.8K +$21.4K +4,070 +41%
NFA
45
Nationwide Fund Advisors
Ohio
$76K – – –
CS
46
Credit Suisse
Switzerland
$69K +$64.9K +12,362 New
VOYA Investment Management
47
VOYA Investment Management
Georgia
$69K +$65.5K +12,471 New
BA
48
BlackRock Advisors
Delaware
$62K +$882 +168 +2%
PVH
49
Psagot Value Holdings
Israel
$43K -$21.5K -4,099 -35%
CG
50
Cutler Group
California
$38K -$27.4K -5,223 -43%
1
2
3

GNMX Hedge Fund Activity: Q2 2016 in Review

69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q2 2016, worth a combined $94.1M — up 59% from $59.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GNMX positions and 2 closed out — a net gain of 13 holders — while 26 added to existing stakes and 15 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $4.46M. The largest seller was LPL Financial, cutting an estimated $239K.

  • 69 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q2 2016, up from 56 in Q1 2016.
  • Funds reported $94.1M of Aevi Genomic Medicine Inc stock for Q2 2016, up 59% quarter-over-quarter.
  • 15 funds opened new Aevi Genomic Medicine Inc positions in Q2 2016 and 2 closed out, a net change of +13 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q2 2016 was Adage Capital Partners, an estimated $4.46M added.
  • The largest Aevi Genomic Medicine Inc seller in Q2 2016 was LPL Financial, an estimated $239K sold.

Based on aggregated 13F filings for Q2 2016.